Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor/ligand 1 (PD-1/PD-L1) pathway have shown significant efficacy in non-small-cell lung cancer (NSCLC).
• The efficacy of PD-1/PD-L1 inhibitors in NSCLC patients with epidermal growth factor receptor (EGFR) activating mutations remains largely undefined.
• EGFR signaling influences the tumor immune microenvironment by regulating MHC class I/II expression, PD-L1 on tumor cells, and lymphocyte activity.

Purpose of the Study:

• To review the regulatory effects of EGFR signaling on the PD-1/PD-L1 pathway in NSCLC.
• To explore potential mechanisms for combining EGFR-tyrosine kinase inhibitors (TKIs) with PD-1/PD-L1 inhibitors.
• To evaluate current data on PD-1/PD-L1 inhibitors (as monotherapy or combined with EGFR-TKIs) in NSCLC with EGFR activating mutations.

Main Methods:

• Literature review of preclinical studies and clinical data.
• Analysis of the immunomodulatory effects of EGFR signaling.
• Discussion of factors influencing treatment efficacy.

Main Results:

• Preclinical evidence suggests EGFR signaling modulates immune responses relevant to PD-1/PD-L1 blockade.
• Combination therapy of EGFR-TKIs and PD-1/PD-L1 inhibitors may be a viable strategy for EGFR-mutated NSCLC.
• Current data on combination therapies in this patient population is being reviewed.

Conclusions:

• EGFR signaling impacts the PD-1/PD-L1 pathway, suggesting a rationale for combined therapeutic approaches.
• Further investigation and clinical trials are needed to determine the optimal use of PD-1/PD-L1 inhibitors, alone or with EGFR-TKIs, in NSCLC patients with EGFR activating mutations.
• Identifying factors influencing efficacy is crucial for future clinical trial design and patient selection.